ongoing

The TheRAPy vanguard is a pragmatic, multicentre, cluster-randomized, crossover trial that will determine the feasibility of studying whether an institutional policy of routine use of autologous priming reduces red blood cell transfusion up to 72 hours after cardiac surgery when compared with a policy of crystalloid priming.

Learn More about TheRAPY
Study Type

Pragmatic Clinical Trial - vanguard phase

Study Design

Multicentre, cluster-randomized, crossover trial - vanguard phase

NO. of Countries

1

NO. of Sites

4

NO. of Participants

4,500

Study Period

2024-2026

Sponsor

PHRI

Hamilton Academic Health Sciences Organization (HAHSO)

Accelerating Clinical Trials (ACT) Consortium

Back To Top